Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMT + harmine is a combination of N,N-dimethyltryptamine (DMT), a potent psychedelic tryptamine, and harmine, a reversible inhibitor of monoamine oxidase A (MAO-A). This combination is inspired by the traditional Amazonian brew ayahuasca. When administered together, harmine inhibits MAO-A in the gut and liver, preventing the rapid breakdown of orally or nasally administered DMT. This allows DMT to become bioavailable and active for an extended period when taken by routes other than smoking or injection. The result is a phenomenologically rich psychedelic experience characterized by vivid visual hallucinations, mystical experiences, psychological insights, emotional breakthroughs, and lasting positive effects on well-being[1][2][3]. Harmine alone has minimal psychoactive effects at tolerated doses but enables the oral activity of DMT through MAO-A inhibition[4][6][7]. The combination can be delivered via various routes (e.g., nasal spray for DMT with buccal/oral tablet for harmine) and produces effects similar to those reported in ayahuasca ceremonies[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dmt + harmine.